Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $129.02.

Several equities research analysts recently issued reports on MRNA shares. Canaccord Genuity Group boosted their price target on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research note on Friday, May 3rd. Evercore ISI started coverage on Moderna in a research note on Tuesday, May 14th. They issued an “in-line” rating and a $120.00 price target for the company. Royal Bank of Canada boosted their price target on Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research note on Monday, June 3rd. Jefferies Financial Group restated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Finally, Oppenheimer boosted their price objective on shares of Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, June 12th.

Insider Activity

In other Moderna news, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the sale, the president now owns 1,486,241 shares of the company’s stock, valued at approximately $156,085,029.82. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CFO James M. Mock sold 705 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $101.93, for a total value of $71,860.65. Following the completion of the transaction, the chief financial officer now owns 5,048 shares of the company’s stock, valued at $514,542.64. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the completion of the sale, the president now directly owns 1,486,241 shares in the company, valued at approximately $156,085,029.82. The disclosure for this sale can be found here. In the last quarter, insiders sold 411,255 shares of company stock worth $55,846,531. 15.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Moderna

A number of institutional investors have recently modified their holdings of MRNA. EverSource Wealth Advisors LLC raised its stake in Moderna by 49.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 712 shares of the company’s stock valued at $79,000 after purchasing an additional 237 shares during the last quarter. DekaBank Deutsche Girozentrale increased its stake in shares of Moderna by 14.3% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 221,718 shares of the company’s stock valued at $24,697,000 after acquiring an additional 27,705 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its stake in shares of Moderna by 13.7% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 272,081 shares of the company’s stock valued at $28,993,000 after acquiring an additional 32,806 shares during the last quarter. Cetera Advisors LLC increased its stake in shares of Moderna by 198.1% during the 1st quarter. Cetera Advisors LLC now owns 12,669 shares of the company’s stock valued at $1,350,000 after acquiring an additional 8,419 shares during the last quarter. Finally, Cetera Investment Advisers increased its stake in shares of Moderna by 584.2% during the 1st quarter. Cetera Investment Advisers now owns 68,390 shares of the company’s stock valued at $7,288,000 after acquiring an additional 58,394 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Trading Up 0.8 %

Shares of NASDAQ:MRNA opened at $134.40 on Friday. Moderna has a 12-month low of $62.55 and a 12-month high of $170.47. The stock has a market cap of $51.51 billion, a PE ratio of -8.58 and a beta of 1.54. The business has a 50 day moving average of $131.11 and a 200-day moving average of $109.71. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. During the same quarter in the previous year, the company posted $0.19 earnings per share. The business’s revenue was down 91.0% on a year-over-year basis. As a group, equities research analysts forecast that Moderna will post -7.46 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.